Biopharmx Corporation. Common (BPMX) Tops Q3 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Trump threatens to bomb Oman over Iran stance
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
BioPharmX Corporation Reports Third Quarter Financial Results
December 14, 2015 4:05 PM ESTMENLO PARK, Calif., Dec. 14, 2015 /PRNewswire/ -- BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical company focusing on dermatology and women's health, today announced its financial results for the third fiscal quarter ended October 31, 2015.
Recent Highlights:
Completed a direct investment of approximately $5.9 million in gross proceeds through the sale of 4,100,000 shares of the company's common stock at a purchase price of $1.43 per share to investment vehicles of Franklin Advisers. Announced early positive pre-clinical data for BPX-01,... More